Meisel, Jane L <br/><br/>
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.  [electronic resource] 

 -  Clinical breast cancer  02 2020 
 - 19-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1938-0666 
<br/><br/><label>Standard No.: </label>10.1016/j.clbc.2019.09.003  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Biomarkers, Tumor--analysis<br/>Breast--immunology<br/>Breast Neoplasms--genetics<br/>Carcinoma, Ductal, Breast--genetics<br/>Chemotherapy, Adjuvant--methods<br/>DNA Copy Number Variations<br/>Drug Resistance, Neoplasm--genetics<br/>Feasibility Studies<br/>Female<br/>Humans<br/>Lymphocytes, Tumor-Infiltrating--immunology<br/>Mastectomy<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Predictive Value of Tests<br/>Progression-Free Survival<br/>Receptor, ErbB-2--antagonists & inhibitors<br/>Receptors, Estrogen--analysis<br/>Receptors, Progesterone--analysis<br/>Tumor Burden